A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients With Uncontrolled Gout Who Have Undergone Kidney Transplantation

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2022 Results evaluating the pharmacokinetics (PK) and immunogenicity of pegloticase in uncontrolled gout pts with a history of KT on immunosuppression, presented at the ACR Convergence 2022.
08 Jun 2022 Results of provisional data analysis presented at the 2022 American Transplant Congress
04 Jun 2022 Results assessing the results of clinically important efficacy endpoints as supportive evidence for the efficacy of pegloticase in kidney transplant patients on immunosuppression presented at the 23rd Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com